商品名: Keytruda/可瑞达价格 通用名:Pembrolizumab Injection/帕博利珠单抗注射液 制药商:MSD/默沙东制药 规格: 4ml:100mg瓶/盒 索引:帕博利珠单抗(K药)
【英文名称】KEYTRUDA Injection(Pembrolizumab(Genetical Recombination)) 【中文名称】派姆单抗重组注射剂 派姆单抗剂量和给药方法 ⑴每3周给予2 mg/kg作为历时30分钟静脉输注。 ⑵ 静脉输注前重建和稀释。 剂型和规格 ⑴ 为注射:50mg,为重建在一次性使用小瓶中冰冻干燥粉。 ⑵ 注射用: 100mg/4mL(25 mg/mL)溶...
Active ingredient: pembrolizumab Inactive ingredients: L-histidine, polysorbate 80, sucrose, and water for injectionWho makes Keytruda?Keytruda is manufactured by Merck & Co. (known as MSD outside the United States and Canada), and their global headquarters are located in Rahway, New Jersey, USA...
About KEYTRUDA® (pembrolizumab) injection, 100 mg KEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor ...
About KEYTRUDA® (pembrolizumab) injection, 100 mg KEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cel...
一.K药,新的适应症也已经提交上市申请: 1.2018年7月25日,默沙东PD-1单抗Keytruda(帕博利珠单抗)-Pembrolizumab的中国上市申请(JXSS1800002)正式获得国家药品监督管理局(NMPA)批准,成为继百时美施贵宝Opdivo之后第2个正式在中国上市的PD-1/PD-L1单抗类药物。第一个
About Keytruda®(pembrolizumab) injection, 100 mg Keytruda is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. Keytruda is a humanized monoclonal antibody that blocks the in...
KEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S. Approval: 2014 - RECENT MAJOR CHANGES - Indications and Usage (1.2) 10/2015 Dosage and Administration (2.1, 2.3) 10/2015 Dosage and Administration (2.4) 01/2015 ...
KEYTRUDA (pembrol 2、izumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S. Approval: 2014 - RECENT MAJOR CHANGES - Indications and Usage (1.2) 10/2015 Dosage and Administration (2.1, 2.3) 10/2015 Dosage and Administration (2.4) 01/...
Pembrolizumab is available as Keytruda as 100 mg/4 mL (25 mg/mL) single-dose vials for intravenous infusion. Monotherapy: Adult individuals with unresectable or metastatic melanoma: 200 mg every 3 weeks or 400 mg every 6 weeks until disease progression or unacceptable toxicity ...